Beam Therapeutics to Participate in Jefferies Global Healthcare Conference
Beam Therapeutics (BEAM), a biotech firm specializing in precision genetic medicines through base editing, announced its participation in the Jefferies Global Healthcare Conference. Giuseppe Ciaramella, President of Beam, will engage in a fireside chat on June 6, 2024, at 1:30 p.m. ET in New York City. The presentation will be webcasted live on Beam's investor website and archived for 60 days.
- Beam Therapeutics' participation in a high-profile event like the Jefferies Global Healthcare Conference can increase visibility.
- The fireside chat with Beam's President provides an opportunity to communicate strategic plans and progress to investors.
- The live webcast and 60-day archive increase accessibility for investors and analysts, potentially boosting investor confidence.
- The announcement lacks specific updates on product development, financial performance, or clinical trial results, which may leave some investors wanting more substantive information.
- Merely participating in a conference, without new data or breakthroughs, may not significantly impact stock performance.
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, president of Beam, plans to participate in a fireside chat during the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 1:30 p.m. ET in New York City.
A live webcast will be available in the investor section of the company's website at www.beamtx.com, and will be archived for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Contacts:
Investors:
Holly Manning
THRUST Strategic Communications
holly@thrustsc.com
Media:
Dan Budwick
1AB
dan@1abmedia.com
FAQ
What is the date and time of Beam Therapeutics' participation in the Jefferies Global Healthcare Conference?
Where can I watch the live webcast of Beam Therapeutics at the Jefferies Global Healthcare Conference?
How long will the webcast of Beam Therapeutics' presentation be archived?
Who will represent Beam Therapeutics at the Jefferies Global Healthcare Conference?
What is Beam Therapeutics' stock symbol?
